Portal de investigação
Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Garcia, Bruno
- ter Schiphorst, Benoit
- Santos, Karine
- Su, Fuhong
- Dewachter, Laurence
- Rocha-Oliveira, Estela
- Roncon-Albuquerque Jr, Roberto
- Uba, Theo
- Hartmann, Oliver
- Picod, Adrien
- Azibani, Feriel
- Callebert, Jacques
- Goldman, Serge
- Annoni, Filippo
- Favory, Raphael
- Vincent, Jean-Louis
- Creteur, Jacques
- Taccone, Fabio Silvio
- Mebazaa, Alexandre
- Herpain, Antoine
Unidades de investigação
Abstract
Background Dipeptidyl peptidase 3 (DPP3) is a ubiquitous cytosolic enzyme released into the bloodstream after tissue injury, that can degrade angiotensin II. High concentrations of circulating DPP3 (cDPP3) have been associated with worse outcomes during sepsis. The aim of this study was to assess the effect of Procizumab (PCZ), a monoclonal antibody that neutralizes cDPP3, in an experimental model of septic shock.Methods In this randomized, open-label, controlled study, 16 anesthetized and mechanically ventilated pigs with peritonitis were randomized to receive PCZ or standard treatment when the mean arterial pressure (MAP) dropped below 50 mmHg. Resuscitation with fluids, antimicrobial therapy, peritoneal lavage, and norepinephrine was initiated one hour later to maintain MAP between 65-75 mmHg for 12 h. Hemodynamic variables, tissue oxygenation indices, and measures of organ failure and myocardial injury were collected. Organ blood flow was assessed using isotopic assessment (99mtechnetium albumin). cDPP3 activity, equilibrium analysis of the renin-angiotensin system and circulating catecholamines were measured. Tissue mRNA expression of interleukin-6 and downregulation of adrenergic and angiotensin receptors were assessed on vascular and myocardial samples.Results PCZ-treated animals had reduced cDPP3 levels and required less norepinephrine and fluid than septic control animals for similar organ perfusion and regional blood flow. PCZ-treated animals had less myocardial injury, and higher PaO2/FiO2 ratios. PCZ was associated with lower circulating catecholamine levels; higher circulating angiotensin II and higher angiotensin II receptor type 1 myocardial protein expression, and with lower myocardial and radial artery mRNA interleukin-6 expression.Conclusions In an experimental model of septic shock, PCZ administration was associated with reduced fluid and catecholamine requirements, less myocardial injury and cardiovascular inflammation, along with preserved angiotensin II signaling.
Dados da publicação
- ISSN/ISSNe:
- 2197-425X,
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 38849640
Intensive Care Medicine Experimental Springer Science and Business Media Deutschland GmbH
Citações Recebidas na Web of Science: 7
Documentos
- Não há documentos
Filiações
Keywords
- Sepsis; Angiotensin II; Dipeptidyl peptidase 3; Vasopressors; Renin-angiotensin system; Shock
Projetos associados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Comparação de escala de qualidade de vida na insuficiência cardíaca com fração de ejeção reduzida quando realizada no domicílio ou na consulta hospitalar.
Investigador Principal: Francisco Aguiar Vasques Novoa Faria
Estudo Observacional Académico (QualidadeIC) . 2021
Citar a publicação
Garcia B,ter B,Santos K,Su F,Dewachter L,Vasques F,Rocha E,Roncon R,Uba T,Hartmann O,Picod A,Azibani F,Callebert J,Goldman S,Annoni F,Favory R,Vincent J,Creteur J,Taccone FS,Mebazaa A,Herpain A. Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury. Intensive Care Med. Exp. 2024. 12. (1):53.
